Company Filing History:
Years Active: 2012
Title: The Innovations of Fracesco Colotta
Introduction
Fracesco Colotta is a notable inventor based in L'Aquila, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit chemotaxis in immune cells. His work is crucial for advancing treatments for various inflammatory conditions.
Latest Patents
Colotta holds a patent for "Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells." This patent describes (R)-2-Arylpropionamide compounds that are effective in preventing and treating tissue damage caused by excessive recruitment of immune cells at inflammatory sites. The compounds are particularly useful in treating conditions such as psoriasis, ulcerative colitis, glomerular nephritis, and rheumatoid arthritis.
Career Highlights
Colotta is associated with Dompé Pharma S.p.A., a company known for its innovative pharmaceutical solutions. His research focuses on the development of dual inhibitors that target both C5a-induced chemotaxis of neutrophils and monocytes, as well as IL-8-induced chemotaxis of PMN leukocytes. This innovative approach has the potential to improve treatment outcomes for patients suffering from various inflammatory diseases.
Collaborations
Colotta has collaborated with notable colleagues, including Marcello Allegretti and Riccardo Bertini. Their combined expertise has contributed to the advancement of research in the field of immunology and pharmacology.
Conclusion
Fracesco Colotta's work exemplifies the impact of innovative research in the pharmaceutical industry. His contributions to the development of new therapeutic compounds are paving the way for improved treatments for inflammatory diseases.